BodenWE, O'RourkeRA, TeoKK. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med2007; 356: 1503–16.
2.
WindeckerS, KolhP, AlfonsoF. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg2014; 46: 517–92.
3.
MontalescotG, SechtemU, AchenbachS. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J2013; 34: 2949–3003.
4.
RidkerPM, EverettBM, ThurenT. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med2017; 377: 1119–31.
5.
NichollsSJ, PuriR, AndersonT. Effect of evolocumab on progression of coronary disease in statin-treated patients – The GLAGOV randomized clinical trial. JAMA2016; 316: 2373–84.
6.
SabatineMS, GiuglianoRP, KeechAC. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med2017; 376: 1713–22.
7.
Al-LameeR, ThompsonD, DehbiHM. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet2018; 391: 31–40.
8.
BrownDL, RedbergRF. Last nail in the coffin for PCI in stable angina?Lancet2018; 391: 3–4.
9.
NudiF, SchillaciO, NeriG, Prognostic impact of location and extent of vessel-related ischaemia at myocardial perfusion scintigraphy in patients with or at risk for further coronary artery disease. J Nucl Cardiol2016; 23: 274–84.
10.
MohrFW, MoriceMC, KappeteinPA. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet2013; 381: 629–38.
11.
De BruyneB, PijlsN, KalesanB. Fractional flow reserve guided PCI versus medical therapy in stable coronary artery disease. N Engl J Med2012; 367: 991–1001.
12.
ZimmermanFM, FerraraA, JohnsonSP. Deferral v performance of percutaneous coronary intervention of functionally non-significant coronary stenosis: 15 year follow up of the DEFER trial. Eur Heart J2015; 36: 3182–8.
13.
PijlsNH, FearonWF, ToninoPA. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study. J Am Coll Cardiol2010: 56;177–84.
14.
BostickNA, SadeR, LevineMA, StewartDMJr. Placebo use in clinical practice: report of the American Medical Association Council on Ethical and Judicial Affairs. J Clin Ethics2008; 19: 58–61.
15.
VerheyeS, JolicœurEM, BehanMW, Efficacy of a device to narrow the coronary sinus in refractory angina. N Engl J Med2015; 372: 519–27.
16.
StergiopoulosK, BodenWE, HartiganP. Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: a collaborative meta-analysis of contemporary randomized clinical trials. JAMA Intern Med2013; 174: 232–40.
17.
BarbatoE, TothGG, JohnsonNP. A prospective natural history study of coronary atherosclerosis using fractional flow reserve. J Am Coll Cardiol2016; 68: 2247–55.
18.
SpertusJA, MaronDJ, CohenDJ. Frequency, predictors, and consequences of crossing over to revascularization within 12 months of randomization to optimal medical therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial. Circ Cardiovasc Qual Outcomes2013; 6: 409–18.
19.
WeintraubWS, SpertusJA, KolmP. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med2008; 359: 677–87.
